Oakland, California
United States
46
2026-05-28
The entities that hold a legal rights for patent applications filed by inventor VAN BLARCOM Thomas John:
Thomas John VAN BLARCOM from Oakland, US has applied for patents for these inventions. The list has both pending applications and granted patents:
SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#2 | 2026-04-30SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#3 | 2026-04-23SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#4 | 2026-02-12SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#5 | 2025-10-30INDUCIBLE CHIMERIC CYTOKINE RECEPTORS
#6 | 2025-07-17CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED SIGNALING AND ACTIVITIES AND USES THEREOF
#7 | 2025-05-08CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
#8 | 2025-02-13CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORS
#9 | 2025-01-09ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES
#10 | 2024-12-26MODIFIED CASPASE-9 POLYPEPTIDES AND METHODS OF USE THEREOF
#11 | 2024-07-11CD70 ANTI-IDIOTYPE ANTIBODIES
#12 | 2024-07-04CLAUDIN 18.2 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS AND USES THEREOF
#13 | 2024-04-18Antibodies Specific for CD47, PD-L1, and Uses Thereof
#14 | 2024-03-28B-CELL MATURATION ANTIGEN (BCMA) ANTI-IDIOTYPIC ANTIBODIES
#15 | 2024-01-18THERAPEUTIC ANTIBODIES AND THEIR USES
#16 | 2024-01-18CHIMERIC CYTOKINE RECEPTORS BEARING A PD-1 ECTODOMAIN
#17 | 2023-09-14DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS
#18 | 2023-06-22ANTIBODIES HAVING CONDITIONAL AFFINITY AND METHODS OF USE THEREOF
#19 | 2023-01-05Antibodies specific for CD70 and their uses
#20 | 2022-12-29SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#21 | 2022-10-27Chimeric antigen receptors targeting B-cell maturation antigen
#22 | 2022-09-08FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH
#23 | 2022-08-11KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
#24 | 2022-07-28Modified caspase-9 polypeptides and methods of use thereof
#25 | 2022-07-21PROTEASE-ACTIVATING CD45-GATE CAR
#26 | 2022-01-27Chimeric antigen receptors with enhanced signaling and activities and uses thereof
#27 | 2021-08-26BCMA CAR-T cells with enhanced activities
#28 | 2021-06-24Therapeutic antibodies and their uses
#29 | 2021-06-17Antibodies specific for CD47, PD-L1, and uses thereof
#30 | 2021-04-15DLL3 targeting chimeric antigen receptors and binding agents
#31 | 2021-03-04CHIMERIC CYTOKINE RECEPTORS COMPRISING TGF BETA BINDING DOMAINS
#32 | 2021-02-25Therapeutic antibodies and their uses
#33 | 2020-12-24IMPROVED T CELL COMPOSITIONS AND METHODS
#34 | 2020-09-17Constitutively active chimeric cytokine receptors
#35 | 2020-09-03Chimeric cytokine receptors bearing a PD-1 ectodomain
#36 | 2019-09-26Inducible chimeric cytokine receptors
#37 | 2019-08-08Chimeric antigen receptors targeting B-cell maturation antigen
#38 | 2019-08-01Antibodies specific for CD70 and their uses
#39 | 2019-08-01Chimeric antigen receptors targeting CD70
#40 | 2019-05-02Modified caspase-9 polypeptides and methods of use thereof
#41 | 2018-10-18Therapeutic antibodies and their uses
#42 | 2018-06-21Therapeutic antibodies and their uses
#43 | 2016-10-27ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
#44 | 2016-10-13Therapeutic antibodies and their uses
#45 | 2016-10-13Chimeric antigen receptors targeting B-cell maturation antigen
#46 | 2014-11-13Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
967449 ⎘